ArticleIntegrative cancer therapies
Potential Interactions of Biologically Based Complementary Medicine in Gynecological Oncology.
Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Exploring biologically-based complementary and alternative medicine use among Irish cancer survivors: findings from a national survey.The oncologist · 2026Article
- Herbal Medicines and Drugs Interactions: Cytochrome P450 Responsibility.Current medicinal chemistry · 2026Review
- Exploring the gap: attitudes, knowledge, and training needs in complementary and integrative medicine among healthcare professionals at German university hospitals.Frontiers in medicine · 2024Article
- Biologically Based Complementary and Alternative Medicine Use in Breast Cancer Patients and Possible Drug-Drug Interactions.Breast care (Basel, Switzerland) · 2023Article
- Complementary and alternative medicine in oncology: knowledge, attitude and practice among Tunisian healthcare workers.Journal of cancer research and clinical oncology · 2023Article
- Real-world Evidence of the Herb-drug Interactions.Journal of food and drug analysis · 2022Review
- Effects of Complementary and Alternative Medicine on Chemotherapy Delivery in Thai Patients.Asian Pacific journal of cancer prevention : APJCP · 2021Observational
- The trends of complementary alternative medicine use among cancer patients.BMC complementary medicine and therapies · 2021Article
- Patterns and Trends of Herbal Medicine Use among Patients with Gynecologic Cancer.Geburtshilfe und Frauenheilkunde · 2021Article
- The Use of Complementary and Alternative Medicine in Thai Gynecologic Oncology Patients: Influencing Factors.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- The usage of over-the-counter products by private insured patients in Germany - a claims data analysis with focus on complementary medicine.BMC health services research · 2020Article
- Biologically-Based Complementary and Alternative Medicine (CAM) Use in Cancer Patients: The Good, the Bad, the Misunderstood.Frontiers in nutrition · 2019Review
- Evaluation of an Expert Guided Integrative Therapy Concept in Patients With Breast or Gynecological Cancer During Systemic Therapy.Journal of evidence-based integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to assess the potential risks of interactions between biologically based complementary and alternative medication (BB-CAM) and conventional drugs during systemic therapy in breast and gynecological cancer patients by analyzing the actual CAM-drug combinations from individual patients' records.
methodsFrom September 2014 to December 2014 and from February 2017 to May 2017, all patients (n = 717) undergoing systemic therapy at the Gynecologic Oncology Day Care Unit in the Gynecology and Obstetrics Department of the Technical University of Munich, Germany, were asked to participate in a questionnaire about all their medications. To assess the potential risk of CAM-drug interactions (CDIs), we initially utilized the Lexicomp drug interaction database. This assessment was then expanded with a systematic search of other digital databases, such as the National Center for Complementary and Integrative Health, Memorial Sloan Kettering Cancer Center, PubMed, and MEDLINE as well as the Cochrane Library.
resultsAmong 448 respondents, 74.1% reported using BB-CAM simultaneously with their systemic therapy. The assessment showed 1 patient with a potentially clinically relevant CDI, where the interaction was based on a self-medicated combination of Echinacea and cyclophosphamide. Furthermore, 81 patients (18.1%) were thought to have interactions because of a combination of BB-CAMs and cytochrome P450 3A4-metabolized anticancer drugs.
conclusionsOur data demonstrated high overall use of BB-CAMs by cancer patients undergoing systemic therapy. The analyses showed only 1 clinically relevant CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.